About CRYOFOCUS-B Company

Kangfeng Biotechnology (Shanghai) Co., Ltd. (formerly Kangfeng Biotechnology (Shanghai) Co., Ltd.) was established in 2013. It is a leading cryomedicine technology platform company with unique advantages in the field of minimally invasive interventional cryotherapy. With its unique liquid nitrogen cryoablation technology, the company is committed to building a comprehensive product portfolio, mainly focusing on two major treatment areas: (i) vascular intervention to treat major cardiovascular diseases, such as atrial fibrillation and high blood pressure; and (ii) through natural cavities to treat respiratory, urinary, and digestive diseases, such as chronic obstructive pulmonary disease, asthma, airway stenosis, bladder cancer, stomach cancer, and esophageal cancer. The company's core team members have more than ten years of research and development experience in medical device-related products and practical engineering applications. They specialize in cryoablation technology, and have successfully developed more than 10 international/domestic pioneering cryoablation products. They have obtained 105 patents and 43 patents are being applied for. At present, the company has successfully developed a number of leading domestic or international cryoablation products, and is committed to making advanced cryoablation technology benefit patients.